The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 18, 2017
Filed:
Nov. 05, 2012
Applicant:
Yeda Research and Development Co. Ltd., Rehovot, IL;
Inventors:
Assignee:
YEDA RESEARCH AND DEVELOPMENT CO. LTD., Rehovot, IL;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 35/26 (2015.01); A61K 35/28 (2015.01); A61K 38/00 (2006.01); A61K 35/17 (2015.01); A61K 31/137 (2006.01); A61K 31/197 (2006.01); A61K 31/4245 (2006.01); C12N 5/0783 (2010.01); A61K 31/135 (2006.01); A61K 31/185 (2006.01); A61K 31/196 (2006.01); A61K 31/661 (2006.01); A61K 31/675 (2006.01); A61K 31/7076 (2006.01); A61K 39/395 (2006.01); A61K 47/48 (2006.01); A61K 48/00 (2006.01); A61N 5/10 (2006.01); B82Y 5/00 (2011.01); A61K 35/12 (2015.01);
U.S. Cl.
CPC ...
A61K 35/17 (2013.01); A61K 31/135 (2013.01); A61K 31/137 (2013.01); A61K 31/185 (2013.01); A61K 31/196 (2013.01); A61K 31/197 (2013.01); A61K 31/4245 (2013.01); A61K 31/661 (2013.01); A61K 31/675 (2013.01); A61K 31/7076 (2013.01); A61K 39/39541 (2013.01); A61K 47/48369 (2013.01); A61K 47/48723 (2013.01); A61K 48/00 (2013.01); A61N 5/10 (2013.01); B82Y 5/00 (2013.01); C12N 5/0638 (2013.01); A61K 2035/124 (2013.01); C12N 2501/2302 (2013.01); C12N 2501/51 (2013.01); C12N 2501/515 (2013.01); C12N 2501/59 (2013.01);
Abstract
A method of treating a disease, such as cancer, by administering to a subject in need of such treatment an effective amount of allogeneic T cells with a MHC unrestricted chimeric receptor short time after partial lymphodepletion. The method also comprises administering one or more agents that delay egression of the allogeneic T cells from lymph nodes of said subject during adoptive transfer of said allogeneic T cells to the subject by trapping the T cells in the lymph nodes.